Table 1 Patient baseline characteristics by group
Pre-Intervention | Post-Intervention | |||
|---|---|---|---|---|
Active (n = 33) | Control (n = 36) | Active (n = 23) | Control (n = 29) | |
Males (%) | 62% | 51% | ||
Age (years) | 61 (10) | 66 (13) | ||
Prescribed levodopa (%) | 21 (62%) | 25 (71%) | 18 (78%) | 22 (76%) |
Levodopa dose (mg) | 485 (252) | 538 (389) | 511 (306) | 670 (380) |
Prescribed dopamine agonist (%) | 25 (74%) | 25 (71%) | 18 (78%) | 18 (62%) |
Change in levodopa equivalent units | - | - | 51 (148) | 70 (149) |
Number of PD drugs | 2.4 (1.1) | 2.4 (1.3) | 2.4 (1.2) | 2.2 (1.5) |
Number of PD daily doses | 4.0 (2.5) | 4.0 (1.3) | 4 (0.8) | 4 (1.2) |
Number of PD tablets per day | 9 (5) | 9.1 (5) | 9.5 (5) | 9 (5) |
Number of non-PD drugs per day | 2.6 (3) | 2.9 (1.8) | 2.5 (3) | 3.5 (4) |
Total number of tablets per day | 12 (5) | 12 (5) | 13 (7) | 12 (7) |
Number of patients with carer | 6 (18%) | 7 (19%) | ||
Duration of PD (years) | 7.5 (6) | 6.3 (4.1) | - | - |
UPDRS 3 | 30 (12) | 24 (13) | 29 (14) | 28 (14) |
Hoehn & Yahr | 2.4 (0.7) | 2.4 (0.7) | 2.5 (0.7) | 2.5 (0.7) |
Schwab & England | 78 (10) | 76 (14) | 71 (18) | 73 (15) |
MMSE | 28 (2) | 28 (2) | - | - |
Geriatric depression score | 12 (6) | 10 (7) | - | - |
PDQ SI | 30 (15) | 26.5 (18) | 36 (15) | 28 (14) |
Timing adherence, median (IQ) | 17% (9–51) | 21% (10–59) | 39% (22–58) | 20% (10–47)* |